Ok fair point...but I was a Sarepta Pharma (SRPT) shareholder until yesterday. That company underwent a R/S a few months ago, moving shares from the $2 range to the $10 range. After promising trial results the stock was around $42 at yesterday's close. There were key strategic reasons for that company to do a R/S and I think there are some key reasons WGAS is considering one as well.
A R/S is not a death sentence, far from it in some cases. If you read some of the prior posts on this board, some have speculated that a primary driver could be a desire to eliminate some of the flipping common with pennies. So to use the R/S as a reason to stay away without examining all the other key drivers is problematic IMO.
Market Data 
Markets 
AI
